Tumour necrosis factor α: A potential target for the therapy of solid tumours

Lancet Oncology

Volumn 4, Issue 9, 2003, Pages 565-573

  Szlosarek, Peter W ^a   Balkwill, Frances R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANGIOGENIC FACTOR; CELECOXIB; CHEMOKINE; CISPLATIN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; DNA ANTIBODY; DOCETAXEL; DOUBLE STRANDED DNA; ETANERCEPT; GEMCITABINE; GREEN TEA EXTRACT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INFLIXIMAB; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR PROMOTER; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; CYTOKINE RELEASE; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG STRUCTURE; DRUG TARGETING; ENTERITIS; EVIDENCE BASED MEDICINE; HUMAN; HYPOTENSION; IMMUNITY; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN ISOLATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOLID TUMOR; TUBERCULOSIS; ANIMAL; DRUG ANTAGONISM; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141431027     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01196-3     Document Type: Review

References (75)

1. Locksley R.M. Killeen N. Lenardo M.J. et al. The TNF and TNF receptor superfamilies: integrating mammalian biology Cell 104 2001 487-501
2. Carswell E.A. Old L.J. Kassel R.L. et al. An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci USA 72 1975 3666-3670
3. Nauts H.C. Fowler G.A. Bogatko F.H. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man Acta Medica Scandinavia 145 1953 S276
4. Beutler B. Greenwald D. Hulmes J.D. et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin Nature 316 1985 552-554
5. Takeda K. Iwamoto S. Sugimoto H. et al. Identity of differentiation inducing factor and tumour necrosis factor Nature 323 1986 338-340
6. Lejeune F.J. Ruegg C. Lienard D. Clinical applications of TNF-alpha in cancer Curr Opin Immunol 10 1998 573-580
7. Weichselbaum R.R. Kufe D.W. Hellman S. et al. Radiation-induced tumour necrosis factor-a expression: clinical application of transcriptional and physical targeting of gene therapy Lancet Oncol 3 2002 665-671
8. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13 2002 135-141
9. Hanahan D. Weinberg R.A. The hallmarks of cancer Cell 100 2000 57-70
10. Balkwill F. Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357 2001 539-545
11. Tsimberidou A.M. Giles F.J. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies Expert Rev Anticancer Ther 2 2002 277-286
12. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences Cell Signal 14 2002 477-492
13. Aggarwal BB, Samanta A, Feldmann M. Chapters on TNFα and TNF receptors. In: Oppenheim JJ, Feldmann ME (Eds). The Cytokine Reference. London: Academic Press 2000; 413-34 and 1619-32.
14. Chen G. Goeddel D.V. TNF-R1 signaling: a beautiful pathway Science 296 2002 1634-1635
15. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB J Clin Invest 107 2001 241-246
16. Havell E.A. Fiers W. North R.J. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity J Exp Med 167 1988 1067-1085
17. Baxevanis C.N. Voutsas I.F. Tsitsilonis O.E. et al. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice Eur J Immunol 30 2000 1957-1966
18. Moore R.J. Owens D.M. Stamp G. et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis Nat Med 5 1999 828-831
19. Suganuma M. Okabe S. Marino M.W. et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice Cancer Res 59 1999 4516-4518
20. Arnott C.H. Scott K.A. Moore R.J. et al. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway Oncogene 21 2002 4728-4738
21. Roberts R.A. Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis Carcinogenesis 20 1999 1397-1401
22. Knight B. Yeoh G.C. Husk K.L. et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice J Exp Med 192 2000 1809-1818
23. Kitakata H. Nemoto-Sasaki Y. Takahashi Y. et al. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells Cancer Res 62 2002 6682-6687
24. Korner H. Cretney E. Wilhelm P. et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype J Exp Med 191 2000 89-96
25. Orosz P. Echtenacher B. Falk W. et al. Enhancement of experimental metastasis by tumor necrosis factor J Exp Med 177 1993 1391-1398
26. Malik S.T. Naylor M.S. East N. et al. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice Eur J Cancer 26 1990 1031-1034
27. Qin Z. Kruger-Krasagakes S. Kunzendorf U. et al. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis J Exp Med 178 1993 355-360
28. Komori A. Yatsunami J. Suganuma M. et al. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation Cancer Res 53 1993 1982-1985
29. Malik S.T. Griffin D.B. Fiers W. et al. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer Int J Cancer 44 1989 918-925
30. Oliff A. Defeo-Jones D. Boyer M. et al. Tumors secreting human TNF/cachectin induce cachexia in mice Cell 50 1987 555-563
31. Sherry B.A. Gelin J. Fong Y. et al. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models Faseb J 3 1989 1956-1962
32. Cahlin C. Korner A. Axelsson H. et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia Cancer Res 60 2000 5488-5493
33. Yoneda T. Alsina M.A. Chavez J.B. et al. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice J Clin Invest 87 1991 977-985
34. Naylor M.S. Stamp G.W. Foulkes W.D. et al. Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression J Clin Invest 91 1993 2194-2206
35. Naylor M.S. Stamp G.W. Balkwill F.R. Investigation of cytokine gene expression in human colorectal cancer Cancer Res 50 1990 4436-4440
36. Szlosarek PW, Grimshaw MJ, Wilbanks GD, et al. Tumor necrosis factor-a regulation in normal and malignant ovarian epithelium. Proc Am Assoc Cancer Res 2003; 44: (abstr) R5053.
37. Mizokami A. Gotoh A. Yamada H. et al. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line J Urol 164 2000 800-805
38. Vinante F. Rigo A. Tecchio C. et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome Br J Haematol 102 1998 1025-1034
39. Warzocha K. Salles G. Bienvenu J. et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients J Clin Oncol 15 1997 499-508
40. Foa R. Massaia M. Cardona S. et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease Blood 76 1990 393-400
41. Herrmann F. Helfrich S.G. Lindemann A. et al. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukaemia J Clin Oncol 10 1992 631-634
42. Rossi A. Landolfo G. Sassi D. et al. Immunocytochemical increased evidence of inducible nitric oxide synthase, tumor necrosis factor-alpha, and adrenocorticotropic hormone in human peritumoral lymph nodes Appl Immunohistochem Mol Morphol 10 2002 52-56
43. Tselepis C. Perry I. Dawson C. et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action Oncogene 21 2002 6071-6081
44. Wong G.H. Elwell J.H. Oberley L.W. et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor Cell 58 1989 923-931
45. Wu S. Boyer C.M. Whitaker R.S. et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression Cancer Res 53 1993 1939-1944
46. Gaiotti D. Chung J. Iglesias M. et al. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway Mol Carcinog 27 2000 97-109
47. Maeda M. Watanabe N. Okamoto T. et al. Endogenous tumor necrosis factor functions as a resistant factor against adriamycin Int J Cancer 58 1994 376-379
48. Jaiswal M. LaRusso N.F. Burgart L.J. et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism Cancer Res 60 2000 184-190
49. Leibovich S.J. Polverini P.J. Shepard H.M. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha Nature 329 1987 630-632
50. Yoshida S. Ono M. Shono T. et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis Mol Cell Biol 17 1997 4015-4023
51. Cheng N. Chen J. Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism J Biol Chem 276 2001 13771-13777
52. De Cesaris P. Starace D. Starace G. et al. Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression J Biol Chem 274 1999 28978-28982
53. Bussolino F. Camussi G. Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha J Biol Chem 263 1988 11856-11861
54. Leek R.D. Landers R. Fox S.B. et al. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma Br J Cancer 77 1998 2246-2251
55. Battegay E.J. Raines E.W. Colbert T. et al. TNF-alpha stimulation of fibroblast proliferation: dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression J Immunol 154 1995 6040-6047
56. Leber T.M. Balkwill F.R. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF) Br J Cancer 78 1998 724-732
57. Rosen E.M. Goldberg I.D. Liu D. et al. Tumor necrosis factor stimulates epithelial tumor cell motility Cancer Res 51 1991 5315-5321
58. Tisdale M.J. Cachexia in cancer patients Nat Rev Cancer 2 2002 862-871
59. Warzocha K. Ribeiro P. Bienvenu J. et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome Blood 91 1998 3574-3581
60. Davies F.E. Rollinson S.J. Rawstron A.C. et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment J Clin Oncol 18 2000 2843-2851
61. Nakajima K. Sasaki M. Nojima D. et al. Tumor necrosis factor-alpha gene mutations and genotype changes in renal cell carcinoma J Urol 165 2001 612-615
62. Oh B.R. Sasaki M. Perinchery G. et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer J Urol 163 2000 1584-1587
63. Hajeer A.H. Lear J.T. Ollier W.E. et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas Br J Dermatol 142 2000 441-445
64. Ghaderi M. Nikitina L. Peacock C.S. et al. Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden Cancer Epidemiol Biomarkers Prev 9 2000 1067-1070
65. Bienvenu J. Chvetzoff R. Salles G. et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment J Haematol 2 2001 378-384
66. Ramesh G. Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity J Clin Invest 110 2002 835-842
67. Piquet P.F. Collart M.A. Grau G.E. et al. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis J Exp Med 170 1989 655-663
68. Libura J. Bettens F. Radkowski A. et al. Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene Eur Respir J 19 2002 912-918
69. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis Nat Rev Immunol 2 2002 364-371
70. Forster M.D. Braybrooke J. Madhusudan S. et al. A Phase II trial using etanercept, a recombinant tumour necrosis factor anatgonist, in metastatic breast cancer Br J Cancer 86 suppl 2002 15
71. Vassallo R. Matteson E. Thomas C.F. Jr Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition Chest 122 2002 1093-1096
72. Richardson P. Hideshima T. Anderson K. Thalidomide: emerging role in cancer medicine Annu Rev Med 53 2002 629-657
73. Turini M.E. DuBois R.N. Cyclooxygenase-2: a therapeutic target Annu Rev Med 53 2002 35-57
74. Plummer S.M. Holloway K.A. Manson M.M. et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventative agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex Oncogene 18 1999 6013-6020
75. Sueoka N. Suganuma M. Sueoka E. et al. A new function of green tea: prevention of lifestyle-related diseases Ann N Y Acad Sci 928 2001 274-280